Renal disease in scleroderma: An update on evaluation, risk stratification, pathogenesis and management

Current Opinion in Rheumatology

Volumn 24, Issue 6, 2012, Pages 669-676

  Shanmugam, Victoria K ^a   Steen, Virginia D ^a  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

autoantibodies; kidney; renal; scleroderma; scleroderma renal crisis

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENZYME ANTIBODY; RNA POLYMERASE 3 ANTIBODY; UNCLASSIFIED DRUG;

DISEASE ASSOCIATION; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; MORBIDITY; MORTALITY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK; SCLERODERMA; SCLERODERMA RENAL CRISIS; SURVIVAL; VASCULAR DISEASE;

ACUTE KIDNEY INJURY; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIBODIES, ANTINUCLEAR; HUMANS; KIDNEY TRANSPLANTATION; PROGNOSIS; RENAL INSUFFICIENCY; RISK ASSESSMENT; RNA POLYMERASE III; SCLERODERMA, SYSTEMIC; SURVIVAL RATE;

EID: 84866975681     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e3283588dcf     Document Type: Review

References (70)

1. LeRoy EC, Black CM, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15:202-205. (Pubitemid 18073738)
2. LeRoy EC, Medsger TA. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001; 28:1573-1576. (Pubitemid 32660630)
3. Steen VD. The many faces of scleroderma. Rheum Dis Clin North Am 2008; 34:1-15. (Pubitemid 351329460)
4. Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005; 35:35-42. (Pubitemid 41111469)
5. Hissaria P, Lester S, Hakendorf P, et al. Survival in scleroderma: results from the population-based South Australian register. Intern Med J 2011; 41:381-390.
6. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007; 66:940-944. (Pubitemid 46999798)
7. Steen V. Scleroderma renal crisis. Rheum Dis Clin North Am 2003; 29:315-333. (Pubitemid 36765123)
8. Steen VD, Medsger TA Jr, Osial TA Jr, et al. Factors predicting development of renal involvement in progressive systemic sclerosis. Am J Med 1984; 76:779-786. (Pubitemid 14142675)
9. Walker UA, Tyndall A, Czirják L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 2007; 66:754-763. (Pubitemid 46846694)
10. Hashimoto A, Endo H, Kondo H, Hirohata S. Clinical features of 405 Japanese patients with systemic sclerosis. Mod Rheumatol 2012; 22:272-279.
11. Penn H, Howie AJ, Kingdon EJ, et al. Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM 2007; 100:485-494. (Pubitemid 47241915)
12. Teixeira L, Mouthon L, Mahr A, et al. Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients. Ann Rheum Dis 2008; 67:110-116.
13. Helfrich D, Banner B, Steen V, Medsger TJ. Normotensive renal failure in systemic sclerosis. Arthritis Rheum 1989; 32:1128-1134. (Pubitemid 19237867)
14. Trostle D, Bedetti C, Steen V, et al. Renal vascular histology and morphometry in systemic sclerosis: a case-control autopsy study. Arthritis Rheum 1988; 31:393-400. (Pubitemid 18091662)
15. Kovalchik M, Guggenheim S, Silverman M, et al. The kidney in progressive systemic sclerosis: a prospective study. Ann Intern Med 1978; 89:881-887. (Pubitemid 9050988)
16. Meyer O, De Chaisemartin LUC, Nicaise-Roland P, et al. Anti-RNA polymerase iii antibody prevalence and associated clinical manifestations in a large series of French patients with systemic sclerosis: a cross-sectional study. J Rheumatol 2010; 37:125-30.
17. Nikpour M, Hissaria P, Byron J, et al. Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a crosssectional analysis of data from an Australian cohort. Arthritis Res Ther 2011; 13:R211.
18. Graf SW, Hakendorf P, Lester S, et al. South Australian Scleroderma Register: autoantibodies as predictive biomarkers of phenotype and outcome. Int J Rheum Dis 2012; 15:102-109.
19. Emilie S, Goulvestre C, Bé rezné A, et al. Anti-RNA polymerase III antibodies are associated with scleroderma renal crisis in a French cohort. Scand J Rheumatol 2011; 40:404-406.
20. Hesselstrand R, Scheja A, Wuttge D. Scleroderma renal crisis in a Swedish systemic sclerosis cohort: survival, renal outcome, and RNA polymerase III antibodies as a risk factor. Scand J Rheumatol 2012; 41:39-43.
21. Satoh T, Ishikawa O, Ihn H, et al. Clinical usefulness of anti-RNA polymerase III antibody measurement by enzyme-linked immunosorbent assay. Rheumatology 2009; 48:1570-1574.
22. Nguyen B, Assassi S, Arnett F, Mayes M. Association of RNA polymerase III antibodies with scleroderma renal crisis. J Rheumatol 2010; 37:1068.
23. Nguyen B, Mayes MD, Arnett FC, et al. HLA-DRB10407 and 1304 are risk factors for scleroderma renal crisis. Arthritis Rheum 2011; 63:530-534.
24. Aggarwal R, Lucas M, Fertig N, et al. Anti-U3 RNP autoantibodies in systemic sclerosis. Arthritis Rheum 2009; 60:1112-1118.
25. Steen VD, Medsger TA. Long-term outcomes of scleroderma renal crisis. Ann Intern Med 2000; 133:600-603.
26. Avouac J, Walker U, Tyndall A, et al. Characteristics of Joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) Database. J Rheumatol 2010; 37:1488-1501.
27. Steen V, Medsger T Jr. The palpable tendon friction rub: an important physical examination finding in patients with systemic sclerosis. Arthritis Rheum 1997; 40:1146-1151. (Pubitemid 27242303)
28. Steen V. Medsger TA Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 1998; 41:1613-1619. (Pubitemid 28459919)
29. Guillevin L, Bé rezné A, Seror R, et al. Scleroderma renal crisis: a retrospective multicentre study on 91 patients and 427 controls. Rheumatology 2012; 51:460-467.
30. Trang G, Steele R, Baron M, Hudson M. Corticosteroids and the risk of scleroderma renal crisis: a systematic review. Rheumatol Int 2012; 32:645-653.
31. Fonseca C, Renzoni E, Sestini P, et al. Endothelin axis polymorphisms in patients with scleroderma. Arthritis Rheum 2006; 54:3034-3042. (Pubitemid 44497785)
32. Penn H, Quillinan N, Khan K, et al. Targeting the endothelin axis in scleroderma renal crisis: rationale and feasibility.
33. Mouthon L, Mehrenberger M, Teixeira L, et al. Endothelin-1 expression in scleroderma renal crisis. Hum Pathol 2011; 42:95-102.
34. Vancheeswaran R, Magoulas T, Efrat G, Wheeler-Jones C, et al. Circulating endothelin-1 levels in systemic sclerosis subsets: a marker of fibrosis or vascular dysfunction? J Rheumatol 1994; 21:1838-1844. (Pubitemid 24312644)
35. Yanaba K, Asano Y, Tada Y, et al. Increased serum soluble CD147 levels in patients with systemic sclerosis: association with scleroderma renal crisis. Clin Rheumatol 2012; 31:835-839.
36. Fleischmajer R. Gould AB Serum renin and renin substrate levels in scleroderma. Proc Soc Exp Biol Med 1975; 50:374-379.
37. Walker KM, Pope J. Treatment of systemic sclerosis complications: what to use when first-line treatment fails: a consensus of systemic sclerosis experts. Seminars in Arthritis and Rheumatism. Semin Arthritis Rheum 2012; 42:42-55.
38. Walker K, Pope J. Expert Agreement on EULAR/EUSTAR recommendations for the management of systemic sclerosis. J Rheum 2011; 38:1326-1328.
39. Steen V, Costantino J, Shapiro A, Medsger TA, Jr. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 1990; 113:352-357. (Pubitemid 20262820)
40. Whitman Hr, Case D, Laragh J, et al. Variable response to oral angiotensinconverting-enzyme blockade in hypertensive scleroderma patients. Arthritis Rheum 1982; 25:241-248. (Pubitemid 12131683)
41. Caskey F, Thacker E, Johnston P, Barnes J. Failure of losartan to control blood pressure in scleroderma renal crisis. Lancet 1997; 349:620. (Pubitemid 27101895)
42. Cheung WY, Gibson IW, Rush D, et al. Late recurrence of scleroderma renal crisis in a renal transplant recipient despite angiotensin II blockade. Am J Kidney Dis 2005; 45:930-934. (Pubitemid 43181054)
43. Dhaun N, MacIntyre IM, Bellamy COC, Kluth DC. Endothelin receptor antagonism and renin inhibition as treatment options for scleroderma kidney. Am J Kidney Dis 2009; 54:726-731.
44. Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69:1809-1815.
45. Siva B, McDonald SP, Hawley CM, et al. End-stage kidney disease due to scleroderma outcomes in 127 consecutive ANZDATA registry cases. Nephrol Dial Transplant 2011; 26:3165-3171.
46. Chu JK, Folkert VW. Renal function recovery in chronic dialysis patients. Semin Dial 2010; 23:606-613.
47. Howie AJ, Ferreira MAS, Adu D. Prognostic value of simple measurement of chronic damage in renal biopsy specimens. Nephrol Dial Transplant 2001; 16:1163-1169. (Pubitemid 32547370)
48. Batal I, Domsic RT, Shafer A, et al. Renal biopsy findings predicting outcome in scleroderma renal crisis. Hum Pathol 2009; 40:332-340.
49. Penn H, Denton CP. Diagnosis, management and prevention of scleroderma renal disease. Curr Opin Rheumatol 2008; 20:692-696.
50. Gibney EM, Parikh CR, Jani A, et al. Kidney transplantation for systemic sclerosis improves survival and may modulate disease activity. Am J Transplant 2004; 4:2027-2031. (Pubitemid 39611630)
51. Pham P-TT, Pham P-CT, Danovitch GM, et al. Predictors and risk factors for recurrent scleroderma renal crisis in the kidney allograft: case report and review of the literature. Am J Transplant 2005; 5:2565-2569.
52. Anders H, Wiebecke B, Haedecke C, et al. MPO-ANCA-positive crescentic glomerulonephritis: a distinct entity of scleroderma renal disease? Am J Kidney Dis 1999; 33:e3.
53. Mimura I, Hori Y, Matsukawa T, et al. Noncrescentic ANCA-associated renal crisis in systemic sclerosis. Clin Nephrol 2008; 70:183-185.
54. Endo H, Hosono T, Kondo H. Antineutrophil cytoplasmic autoantibodies in 6 patients with renal failure and systemic sclerosis. J Rheumatol1994; 21:864-870. (Pubitemid 24168670)
55. Arad U, Balbir-Gurman A, Doenyas-Barak K, et al. Anti-neutrophil antibody associated vasculitis in systemic sclerosis. Semin Arthritis Rheum 2011; 41:223-229.
56. Derk C, Jimenez S. Goodpasture-like syndrome induced by D-penicillamine in a patient with systemic sclerosis: report and review of the literature. J Rheumatol 2003; 30:1616-1620. (Pubitemid 36835465)
57. Cannon P, Hassar M, Case D, et al. The relationship of hypertension and renal failure in scleroderma (progressive systemic sclerosis) to structural and functional abnormalities of the renal cortical circulation. Medicine (Baltimore) 1974; 53:1-46.
58. Steen VD, Syzd A, Johnson JP, et al. Kidney disease other than renal crisis in patients with diffuse scleroderma. J Rheumatol 2005; 32:649-655. (Pubitemid 40524696)
59. Scheja A, Bartosik I, Wuttge DM, Hesselstrand R. Renal function is mostly preserved in patients with systemic sclerosis. Scand J Rheumatol 2009; 38:295-298.
60. Seiberlich B, Hunzelmann N, Krieg T, et al. Intermediate molecular weight proteinuria and albuminuria identify scleroderma patients with increased morbidity. Clin Nephrol 2008; 70:110-117.
61. François B, Moulin G, Assenat H, et al. The kidney in systemic scleroderma: a report of 38 consecutive cases. Nephrologie 1982; 3:85-91. (Pubitemid 12020601)
62. Livi R, Guiducci S, Perfetto F, et al. Lack of activation of renal functional reserve predicts the risk of significant renal involvement in systemic sclerosis. Ann Rheum Dis 2011; 70:1963-1967.
63. Livi R, Teghini L, Pignone A, et al. Renal functional reserve is impaired in patients with systemic sclerosis without clinical signs of kidney involvement. Ann Rheum Dis 2002; 61:682-686. (Pubitemid 34787704)
64. Kingdon E, Knight C, Dustan K, et al. Calculated glomerular filtration rate is a useful screening tool to identify scleroderma patients with renal impairment. Rheumatology 2003; 42:26-33. (Pubitemid 36131563)
65. Campo A, Mathai SC, Le Pavec J, et al. Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. Am J Respir Crit Care Med 2010; 182:252-260.
66. Mohamed R, Zayed H, Amin A. Renal disease in systemic sclerosis with normal serum creatinine. Clin Rheumatol 2010; 29:729-737.
67. Gigante A, Rosato E, Massa R, et al. Evaluation of Chronic Kidney Disease Epidemiology Collaboration equation to estimate glomerular filtration rate in scleroderma patients. Rheumatology 2012; 51:1426-1431.
68. Rosato E, Gigante A, Barbano B, et al. Intrarenal hemodynamic parameters correlate with glomerular filtration rate and digital microvascular damage in patients with systemic sclerosis. Semin Arthritis Rheum 2012; 41:815-821.
69. Rosato E, Cianci R, Barbano B, et al. N-acetylcysteine infusion reduces the resistance index of renal artery in the early stage of systemic sclerosis. Acta Pharmacol Sin 2009; 30:1283-1288.
70. Shimizu K, Ogawa F, Yoshizaki A, et al. Increased serum levels of soluble CD163 in patients with scleroderma. Clin Rheumatol 2012; 31:1059-1064.